Research Topics
| Louis J AronneSummaryAffiliation: Cornell University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Epidemiology, morbidity, and treatment of overweight and obesityL J Aronne
Comprehensive Weight Control Program, New York, NY, USA
J Clin Psychiatry 62:13-22. 2001..The guidelines from the National Heart, Lung, and Blood Institute of the National Institutes of Health for diagnosing and treating obesity are also discussed...- Managing overweight and obesity in womenJana Klauer
Comprehensive Weight Control Program, New York, New York 10021, USA
Clin Obstet Gynecol 45:1080-8. 2002 - The impact of obesity on cardiometabolic riskLouis J Aronne
New York-Presbyterian Hospital, Weill Cornell Medical College, New York, NY, USA
JAAPA . 2007 
The challenge of treating obesity: the endocannabinoid system as a potential targetKathy Keenan Isoldi
Clinical Nutrition Services, The Comprehensive Weight Control Program, New York, NY, USA
J Am Diet Assoc 108:823-31. 2008..Emerging research data reveals pathways that influence appetite and energy metabolism, and this knowledge may form the foundation for new clinical treatment options for obese individuals...- Emerging pharmacotherapy for obesityLouis J Aronne
Comprehensive Weight Control Program, Weill Cornell Medical College, NY 10065, USA
Expert Opin Emerg Drugs 16:587-96. 2011..This approach would enhance the ability of physicians to practice 'weight-centric' disease management... - Classification of obesity and assessment of obesity-related health risksLouis J Aronne
Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
Obes Res 10:105S-115S. 2002..Gathering this information will allow the clinician to tailor a weight-loss program to each patient individually. Although this represents the most challenging component of obesity care, resources are available to guide the clinician... - The endocannabinoid system as a target for obesity treatmentLouis J Aronne
Weill Cornell Medical College, New York, New York, USA
Clin Cornerstone 9:52-64; discussion 65-6. 2008..Thus, these agents may provide a rational and effective approach for the management of not only overweight and obesity but also their metabolic and cardiovascular sequelae... - Pharmacotherapy for obesityLisa M Neff
Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, Rockefeller University Hospital, 1230 York Avenue, Box 332, New York, NY 10021, USA
Curr Atheroscler Rep 9:454-62. 2007..Important drug targets that are highlighted in this review include adipocyte-derived hormones, hypothalamic neuropeptides, and gastrointestinal hormones... - Therapeutic options for modifying cardiometabolic risk factorsLouis J Aronne
Weill Medical College of Cornell University, Columbia College of Physicians and Surgeons, and the Comprehensive Weight Control Program, New York Presbyterian Hospital, New York, New York 10021, USA
Am J Med 120:S26-34. 2007.... - Weight management for type 2 diabetes mellitus: global cardiovascular risk reductionMichelle Lee
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
Am J Cardiol 99:68B-79B. 2007..Such global risk reduction is crucial for patients with diabetes, in whom CAD is a major cause of mortality... - Adiposity and fat distribution outcome measures: assessment and clinical implicationsLouis J Aronne
Weill Medical College of Cornell University, 1165 York Avenue, New York, NY 10021, USA
Obes Res 10:14S-21S. 2002 - Obesity as a disease state: a new paradigm for diagnosis and treatmentLouis J Aronne
Weill Cornell Medical College, New York, New York, USA
Clin Cornerstone 9:9-25; discussion 26-9. 2009..Several weight loss drugs are available for long-term use, with others in various stages of clinical development... - Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitusLeon I Igel
Department of Medicine, New York Presbyterian Weill Cornell Medical Center, 505 E 70th Street, Suite 450, New York, NY 10021, USA
Curr Atheroscler Rep 14:60-9. 2012..Emphasis is also placed on a proposed paradigm shift from the glucose-centric to the weight-centric management of type 2 diabetes mellitus... - Overweight and obesity: key components of cardiometabolic riskLouis J Aronne
Weill Medical College of Cornell University, New York, New York 10065, USA
Clin Cornerstone 8:29-37. 2007..While there are few medical options currently available, new compounds for the treatment of obesity are under investigation... - Rimonabant: new data and emerging experienceSuzanne M Wright
Comprehensive Weight Control Program, New York Presbyterian Hospital, Weill Medical College of Cornell University, 1165 York Avenue, New York, NY 10065, USA
Curr Atheroscler Rep 10:71-8. 2008..The use of endocannabinoid antagonists such as rimonabant provides a promising therapeutic approach to the treatment of obesity and its associated cardiometabolic risks... - Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trialLouis J Aronne
Weill Cornell Medical College, New York, New York, USA
Obesity (Silver Spring) 18:1739-46. 2010..However, the majority of subjects receiving these treatments remained within normal blood pressure ranges. These results support the potential of pramlintide-containing combination treatments for obesity... - Weight gain in the treatment of mood disordersLouis J Aronne
Comprehensive Weight Control Program, Weill Medical College of Cornell University, New York, N Y, USA
J Clin Psychiatry 64:22-9. 2003..This article provides an overview of the weight-gain potential of several classes of drugs commonly used in psychiatric practice and considerations for clinicians in prescribing these medications... - When prevention fails: obesity treatment strategiesLouis J Aronne
Department of Medicine, Weill Cornell Medical College, and Comprehensive Weight Control Program, New York Presbyterian Hospital, New York, New York 10028, USA
Am J Med 122:S24-32. 2009..Studies are underway to identify new therapeutic strategies to effectively reduce weight, as well as to provide long-term data on successful weight loss maintenance strategies... - Causes of obesitySuzanne M Wright
Comprehensive Weight Control Program, Weill Cornell Medical College New York Presbyterian Hospital, 1165 York Avenue, New York, NY 10065, USA
Abdom Imaging 37:730-2. 2012..The dramatic rise in obesity has also occurred in many other countries, and the causes of this increase are not fully understood (Hill and Melanson, Med Sci Sports Exerc 31:S515-S521, 1999)... - Implantable gastric stimulator does not prevent the increase in plasma ghrelin levels that occurs with weight lossJudith Korner
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
Obesity (Silver Spring) 19:1935-9. 2011..Further studies are needed to determine whether changes in technology can improve weight loss and maintenance, perhaps using gut hormones as biomarkers of possible efficacy... - Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacyLouis J Aronne
Weill Medical College of Cornell University, New York, New York 10021 7917, USA
Am J Cardiol 100:18P-26P. 2007.... - Pharmacological approaches to weight reduction: therapeutic targetsJudith Korner
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
J Clin Endocrinol Metab 89:2616-21. 2004 - Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trialF Xavier Pi-Sunyer
Obesity Research Center, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10025, USA
JAMA 295:761-75. 2006..Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese... - Obesity and pharmacologic therapyMarie Thearle
Department of Preventive Medicine, Columbia University College of Physicians and Surgeons, Russ Berrie Medical Science Pavilion, 1150 St. Nicholas Avenue, Room 238, New York, NY 10032, USA
Endocrinol Metab Clin North Am 32:1005-24. 2003..This weight loss is associated with improvements in blood pressure, insulin sensitivity, and dyslipidemia. Multiple new therapies that target several different regulatory pathways are currently in clinical trials... - Obesity as a disease: etiology, treatment, and management considerations for the obese patientLouis J Aronne
Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
Obes Res 10:95S-96S. 2002 - Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenanceLouis J Aronne
Weill Cornell Medical College, Cornell University, New York, New York, USA
Obesity (Silver Spring) 19:1404-14. 2011..However, the reported increases in psychiatric symptoms were not consistently dose dependent... 
The emerging science of body weight regulation and its impact on obesity treatmentJudith Korner
Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
J Clin Invest 111:565-70. 2003- Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategiesLouis J Aronne
Weill Cornell Medical College of Cornell University, New York, NY The Comprehensive Weight Control Program, 1165 York Avenue, New York, NY 10028
J Clin Lipidol 1:575-82. 2007..The endocannabinoid system is now recognized as a potentially viable pathway to modulate appetite and energy, lipid, and glucose metabolism... - Gastric pacing is not enough: additional measures for an effective obesity treatment programLouis J Aronne
Weill Cornell University Medical College, New York, NY, USA
Obes Surg 14:S23-7. 2004..Thus, gastric stimulation should work best when combined with other treatments such as diet, exercise, and behavioral change... - Medical assessment of obese older patientsAnnamaria Calleo-Cross
Westchester Medical Group, 3020 Westchester Avenue, Purchase, NY 10577, USA
Clin Geriatr Med 21:689-99, v. 2005..In the older patient, building lean body mass with resistance training seems to be of primary importance. A low-glycemic diet composed of healthy foods is recommended... - Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patientsJames L Early
Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, 1010 N Kansas Rd, Wichita, KS 67214 3199, USA
Obesity (Silver Spring) 15:1464-72. 2007..Our objective was to assess the efficacy and safety of sibutramine with a low-calorie diet (LCD) and commercial meal-replacement product in achieving weight loss and weight-loss maintenance in obese patients... - Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesitySteve R Smith
Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA
Diabetes Care 31:1816-23. 2008..To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI)... - Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group IV: prevention/treatmentRebecca M Mullis
Circulation 110:e484-8. 2004